[go: up one dir, main page]

WO2005087216A3 - Traitement d'etats anemiques par inhibition de l'erythrozytenapoptose - Google Patents

Traitement d'etats anemiques par inhibition de l'erythrozytenapoptose Download PDF

Info

Publication number
WO2005087216A3
WO2005087216A3 PCT/EP2005/002495 EP2005002495W WO2005087216A3 WO 2005087216 A3 WO2005087216 A3 WO 2005087216A3 EP 2005002495 W EP2005002495 W EP 2005002495W WO 2005087216 A3 WO2005087216 A3 WO 2005087216A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
inhibition
erythrocyte
erythrocyte apoptosis
anaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/002495
Other languages
German (de)
English (en)
Other versions
WO2005087216A2 (fr
Inventor
Florian Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of WO2005087216A2 publication Critical patent/WO2005087216A2/fr
Publication of WO2005087216A3 publication Critical patent/WO2005087216A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de substances inhibant l'érythrozytenapoptose pour la fabrication d'un médicament destiné au traitement et/ou la prophylaxie d'anémie ou/et de problèmes de microcirculation, un procédé de détection d'une maladie ou d'une prédisposition d'un patient à une anémie et/ou à des problèmes de microcirculation, l'utilisation d'annexine pour la détection d'une maladie ou d'une prédisposition d'un patient à une anémie et/ou à des problèmes de microcirculation in vitro, une solution test de tolérance au glucose, l'utilisation de substances inhibant l'érythrocytenapoptose pour la conservation du sang et de préparations renfermant des globules sanguins, ainsi qu'une composition servant à la conservation du sang et de préparations renfermant des globules sanguins.
PCT/EP2005/002495 2004-03-12 2005-03-09 Traitement d'etats anemiques par inhibition de l'erythrozytenapoptose Ceased WO2005087216A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004013067 2004-03-12
DE102004013067.1 2004-03-12

Publications (2)

Publication Number Publication Date
WO2005087216A2 WO2005087216A2 (fr) 2005-09-22
WO2005087216A3 true WO2005087216A3 (fr) 2006-03-30

Family

ID=34963168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002495 Ceased WO2005087216A2 (fr) 2004-03-12 2005-03-09 Traitement d'etats anemiques par inhibition de l'erythrozytenapoptose

Country Status (1)

Country Link
WO (1) WO2005087216A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007005329A1 (de) 2007-01-29 2008-07-31 Eberhard-Karls-Universität Tübingen Universitätsklinikum Mittel zur Erythrozytenprotektion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2926085A (en) * 1959-04-29 1960-02-23 Petrus J Geerlings Dietary supplement for animals
US4812443A (en) * 1984-06-29 1989-03-14 Kuraray Co., Ltd. Methods for enhancing differentiation and proliferation of hematopoietic progenitor cells
WO1996040038A2 (fr) * 1995-06-07 1996-12-19 Steroidogenesis Inhibitors, Inc. Traitement de l'anemie par des compositions de procaine
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
EP1308155A2 (fr) * 2001-10-12 2003-05-07 Nipro Corporation Solution injectable contenant un colloide de fer et chondroitine sulfate de cartilage de requin
US20030191090A1 (en) * 2002-04-09 2003-10-09 Pharmacosmos Holding A/S Iron dextrin compounds for the treatment of iron deficiency anaemia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2926085A (en) * 1959-04-29 1960-02-23 Petrus J Geerlings Dietary supplement for animals
US4812443A (en) * 1984-06-29 1989-03-14 Kuraray Co., Ltd. Methods for enhancing differentiation and proliferation of hematopoietic progenitor cells
WO1996040038A2 (fr) * 1995-06-07 1996-12-19 Steroidogenesis Inhibitors, Inc. Traitement de l'anemie par des compositions de procaine
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
EP1308155A2 (fr) * 2001-10-12 2003-05-07 Nipro Corporation Solution injectable contenant un colloide de fer et chondroitine sulfate de cartilage de requin
US20030191090A1 (en) * 2002-04-09 2003-10-09 Pharmacosmos Holding A/S Iron dextrin compounds for the treatment of iron deficiency anaemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONNELLY T J ET AL: "The effect of a low-phosphate diet on hematocrit and oxygen transport in uremic rats.", AMERICAN JOURNAL OF HEMATOLOGY. FEB 1982, vol. 12, no. 1, February 1982 (1982-02-01), pages 55 - 61, XP008051467, ISSN: 0361-8609 *
KNOCHEL, THE KIDNEY: PHYSIOLOGY AND PATHOPHYSIOLOGY, no. 72, 1992, pages 2533 - 2562, XP008051470 *
PETRITES-MURPHY M B ET AL: "ROLE OF PARATHYROID HORMONE IN THE ANEMIA OF CHRONIC TERMINAL RENAL DYSFUNCTION IN DOGS", AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 50, no. 11, 1989, pages 1898 - 1905, XP008051466, ISSN: 0002-9645 *
SHELDON: "Phosphate depletion and repletion...", ANN. SURG., 1975, pages 683 - 689, XP008051471 *

Also Published As

Publication number Publication date
WO2005087216A2 (fr) 2005-09-22

Similar Documents

Publication Publication Date Title
MX338384B (es) Suplemento de la dieta materna.
EP4541418A3 (fr) Dosages pour diagnostiquer et évaluer des options de traitement pour la maladie de fabry
CA2633594C (fr) Moyens et procedes pour le traitement de maladies tumorales
PH12013501790B1 (en) Use of dpp iv inhibitors
SG151271A1 (en) Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MXPA05009015A (es) Nuevos derivados de bencimidazol e imidazo-piridina y su utilizacion como medicamentos.
NO20055892L (no) Karboksylsyrederivater
UA101166C2 (ru) Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
MX2010001849A (es) Depsipeptidos ciclicos.
UA83057C2 (ru) Замещенные производные диоксида тиазолбензоизотиазола и их применение
TW200604193A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
SI1778680T1 (sl) Spirociklični cikloheksanski derivati
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
TW200612903A (en) Use of trisubstituted benzopyranones
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
CN107427546B (zh) 含有盘龙参提取物的组合物及其药物应用
WO2009051217A1 (fr) Préparation à absorption percutanée renfermant du fentanyl
WO2005087216A3 (fr) Traitement d&#39;etats anemiques par inhibition de l&#39;erythrozytenapoptose
WO2007027344A3 (fr) Composes et methodes destines au traitement du cancer
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
WO2007070355A3 (fr) Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
ZA200804499B (en) Compounds for the inhibition of apoptosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase